CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate Dilated cardiomyopathy: so many cardiomyopathies!

Guideline2018 Oct 31.

JOURNAL:Heart Rhythm. Article Link

2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Kusumoto FM, Schoenfeld MH, Barrett C et al. Keywords: bradycardia; cardiac conduction delay; guideline; ACC; AHA

FULL TEXT PDF